



November 2, 2007

Achillion to Present At Upcoming Conferences

NEW HAVEN, Conn., Nov 2, 2007 (PrimeNewswire via COMTEX News Network) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, President and Chief Executive Officer of Achillion, will be presenting a corporate overview and update on the Company's clinical programs in HIV, HCV and serious bacterial infections at the following upcoming investment conferences:

- * CIBC World Markets 18th Annual Healthcare Conference -- November 5, 2007 at 1:55 p.m. at the Waldorf-Astoria Hotel in New York City
- * Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference -- November 6, 2007 at 10:15 a.m. at the New York Palace Hotel in New York City
- * JMP Securities Section Focus Conference -- November 13, 2007 at 11:30 a.m. at the Four Seasons Hotel in Boston

The live audio broadcasts and the subsequent archived webcasts of the Company presentations will be available on the Company's website, www.achillion.com, under the "News Center" section. The audio recording will be archived there for 30 days following the live presentation. Please connect to Achillion's website several minutes prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary.

About Achillion

Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The company's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease -- HIV, hepatitis and resistant bacterial infections. For more information on Achillion Pharmaceuticals, please visit the company's web site at www.achillion.com or call Achillion at 1-203-624-7000.

ACHN-G

This news release was distributed by PrimeNewswire, www.primenewswire.com

SOURCE: Achillion Pharmaceuticals, Inc

Achillion Pharmaceuticals, Inc.
Investors:
Mary Kay Fenton
(203) 624-7000
mfenton@achillion.com

MacDougall Biomedical Communications
Media:
Chris Erdman
(508) 647-0209
cerdman@macbiocom.com

(C) Copyright 2007 PrimeNewswire, Inc. All rights reserved.

News Provided by COMTEX